WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

David Kuter, MD, DPhil

Professor of Medicine
Harvard Medical School
Program Director in Hematology
Massachusetts General Hospital
Boston, Massachusetts, United States

Disclosures

David Kuter, MD, DPhil, has the following relevant financial relationships:
Consultant or advisor for: AIRx; Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; Alpine; Amgen, Inc.; Argenx; BioCryst Pharmaceuticals, Inc.; Bioverativ; Bristol Myers Squibb Company; Caremark, L.L.C.; Cellularity; Cellphire; Chugai Pharma USA, LLC; Daiichi Sankyo, Inc.; Dianthus; Dova Pharmaceuticals; Electra Therapeutics; Fuji; HbO2; Hengrui; Immunovant; Incyte Corporation; Inmagene Bio; Kezar Life Sciences; Kyowa Kirin Pharmaceutical Development, Inc.; Merck Sharp & Dohme; Momenta Pharmaceuticals, Inc.; Novartis; Nuvig; Pfizer, Inc.; Platelet Biogenesis; Principia Biopharma; Protagonist; Rigel; Sanofi; Sanofi Genzyme; Swedish Orphan Biovitrum; Syntimmune; Takeda; UCB; Zafgen
Research funding from: Alnylam Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Bioverativ; Novartis; Principia Biopharma; Rigel; Sanofi; Takeda; UCB
Owns stock (publicly traded) in: Rubius Therapeutics

Libor Červinek, MD, PhD

Department of Internal Medicine, Hematology and Oncology
Faculty Hospital Brno
Masaryk University
Brno, Czech Republic

Disclosures

Libor Červinek, MD, PhD, has no relevant financial relationships.

Maria L. Lozano, MD, PhD

Hospital Universitario Morales Meseguer
Centro Regional de Hemodonación
Universidad de Murcia
IMIB-Arrixaca
Murcia, Spain

Disclosures

Maria L. Lozano, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; Argenx; Grifols; Novartis; Swedish Orphan Biovitrum; UCB
Speaker or member of speakers bureau for: Amgen, Inc.; Grifols; Novartis; Swedish Orphan Biovitrum
Research funding from: Amgen, Inc.

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Sanneke Koekoek has no relevant financial relationships.

Chii Shyang Fong, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Optimizing Treatment Selection in Immune Thrombocytopenia: A Patient Case Discussion

Authors: David Kuter, MD, DPhil; Libor Červinek, MD, PhD; Maria L. Lozano, MD, PhD
CPD Released: 6/26/2023
Valid for credit through: 6/26/2024, 11:59 PM EST

Start Activity

Credits Available

Non-US Physicians - maximum of 0.50 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematologists.

The goal of this activity is for learners to be better able to optimally select the most appropriate thrombopoietin receptor agonist (TPO-RA) therapy based on disease-, patient-, and drug-related factors.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent developments in the therapeutic landscape in ITP
Demonstrate greater confidence in their ability to
- Identify patients who will benefit most from the use of TPO-RAs
- Select TPO-RA therapy based on disease-, patient-, and drug-related factors

Disclosures

Disclosures for additional planners can be found here.

Faculty

David Kuter, MD, DPhil

Professor of Medicine
Harvard Medical School
Program Director in Hematology
Massachusetts General Hospital
Boston, Massachusetts, United States

Disclosures

David Kuter, MD, DPhil, has the following relevant financial relationships:
Consultant or advisor for: AIRx; Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc.; Alpine; Amgen, Inc.; Argenx; BioCryst Pharmaceuticals, Inc.; Bioverativ; Bristol Myers Squibb Company; Caremark, L.L.C.; Cellularity; Cellphire; Chugai Pharma USA, LLC; Daiichi Sankyo, Inc.; Dianthus; Dova Pharmaceuticals; Electra Therapeutics; Fuji; HbO2; Hengrui; Immunovant; Incyte Corporation; Inmagene Bio; Kezar Life Sciences; Kyowa Kirin Pharmaceutical Development, Inc.; Merck Sharp & Dohme; Momenta Pharmaceuticals, Inc.; Novartis; Nuvig; Pfizer, Inc.; Platelet Biogenesis; Principia Biopharma; Protagonist; Rigel; Sanofi; Sanofi Genzyme; Swedish Orphan Biovitrum; Syntimmune; Takeda; UCB; Zafgen
Research funding from: Alnylam Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; Bioverativ; Novartis; Principia Biopharma; Rigel; Sanofi; Takeda; UCB
Owns stock (publicly traded) in: Rubius Therapeutics

Libor Červinek, MD, PhD

Department of Internal Medicine, Hematology and Oncology
Faculty Hospital Brno
Masaryk University
Brno, Czech Republic

Disclosures

Libor Červinek, MD, PhD, has no relevant financial relationships.

Maria L. Lozano, MD, PhD

Hospital Universitario Morales Meseguer
Centro Regional de Hemodonación
Universidad de Murcia
IMIB-Arrixaca
Murcia, Spain

Disclosures

Maria L. Lozano, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; Argenx; Grifols; Novartis; Swedish Orphan Biovitrum; UCB
Speaker or member of speakers bureau for: Amgen, Inc.; Grifols; Novartis; Swedish Orphan Biovitrum
Research funding from: Amgen, Inc.

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Sanneke Koekoek has no relevant financial relationships.

Chii Shyang Fong, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

Yaisanet Oyola, MD

Associate Director, Accreditation and Compliance

Disclosures

Yaisanet Oyola, MD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Optimizing Treatment Selection in Immune Thrombocytopenia: A Patient Case Discussion

Authors: David Kuter, MD, DPhil; Libor Červinek, MD, PhD; Maria L. Lozano, MD, PhDFaculty and Disclosures

CPD Released: 6/26/2023

Valid for credit through: 6/26/2024, 11:59 PM EST

processing....

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 4

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

David Kuter, MD, DPhil

Libor Červinek, MD, PhD

Maria L. Lozano, MD, PhD

Editors

Sanneke Koekkoek

Chii Shyang Fong, PhD

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

CPD

Optimizing Treatment Selection in Immune Thrombocytopenia: A Patient Case Discussion

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

David Kuter, MD, DPhil

Libor Červinek, MD, PhD

Maria L. Lozano, MD, PhD

Editors

Sanneke Koekkoek

Chii Shyang Fong, PhD

Compliance Reviewer

Yaisanet Oyola, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Optimizing Treatment Selection in Immune Thrombocytopenia: A Patient Case Discussion

Learning Feedback Questions